SVN-114 selected as the lead candidate for PTSD discovery programme
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (‘CNS’) disorders, announces the selection of SVN-114 as the lead candidate from the Company’s proprietary SVN-SDN-14 discovery programme targeting Post-Traumatic Stress Disorder (‘PTSD’), a condition affecting more than 20 million people worldwide for which effective pharmacological treatment…